Kalaris Therapeutics, Inc. - Asset Resilience Ratio
Kalaris Therapeutics, Inc. (KLRS) has an Asset Resilience Ratio of 57.18% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Kalaris Therapeutics, Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Kalaris Therapeutics, Inc.'s Asset Resilience Ratio has changed over time. See Kalaris Therapeutics, Inc. (KLRS) net asset quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Kalaris Therapeutics, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kalaris Therapeutics, Inc. (KLRS) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.79 Million | 57.18% |
| Total Liquid Assets | $62.79 Million | 57.18% |
Asset Resilience Insights
- Very High Liquidity: Kalaris Therapeutics, Inc. maintains exceptional liquid asset reserves at 57.18% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kalaris Therapeutics, Inc. Industry Peers by Asset Resilience Ratio
Compare Kalaris Therapeutics, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Kalaris Therapeutics, Inc. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Kalaris Therapeutics, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 16.37% | $19.93 Million | $121.74 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $118.55 Million | -- |
| 2021-12-31 | 16.21% | $46.46 Million | $286.59 Million | -46.80pp |
| 2020-12-31 | 63.01% | $233.66 Million | $370.82 Million | +16.40pp |
| 2019-12-31 | 46.62% | $64.99 Million | $139.42 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more